NAFLD vs MASLD (Metabolic Dysfunction–Associated Steatotic Liver Disease)—Why the Need for a Change of Nomenclature?
The Journal of Clinical Endocrinology & Metabolism · 17.06.2025 · 110 (7) · e2407-e2410
DOI: 10.1210/clinem/dgaf094 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, online erschienen am 19.02.2025. Verfasst von Amalia Gastaldelli und 1 weiteren Autor:innen. Beteiligte Einrichtung: Cardiometabolic Risk Laboratory, Institute of Clinical Physiology (IFC), National Research Council (CNR), 56124 Pisa, Italy. Hauptthemen laut MEDLINE: Non-alcoholic Fatty Liver Disease, Terminology as Topic, Fatty Liver, Metabolic Diseases. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 24 Literaturangaben.
Abstract (Originalsprache)
Several reasons led to the change in the nomenclature from nonalcoholic fatty liver disease (NAFLD) to metabolic dysfunction–associated steatotic liver disease (MASLD); the most important being limitations due to the reliance on exclusionary confounder terms and the use of potentially stigmatizing language (the terms “nonalcoholic” and “fatty”). The new name was decided through a Delphi process and now includes in the name, and definition, the metabolic origin (the presence of at least 1 of 5 cardiometabolic risk factors) without the stigmatizing terms. The recognition of a new category termed “metabolic and alcohol related/associated liver disease” (MetALD) opens up a new area for exploration although the relative contribution of alcohol and metabolic risk factors requires further evaluation as does the evidencing at a patient rather than population level.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Cardiometabolic Risk Laboratory, Institute of Clinical Physiology (IFC), National Research Council (CNR), 56124 Pisa, Italy.
- Roger Williams Institute of Liver Studies, School of Immunology & Microbial Sciences, Faculty of Life Sciences and Medicine, King's College London, Foundation for Liver Research and King's College Hospital, London SE5 9…
ORCID-Profile: Amalia Gastaldelli, Philip N Newsome
Zitieren
APA
Gastaldelli, A., & Newsome, P. N. (2025). NAFLD vs MASLD (Metabolic Dysfunction–Associated Steatotic Liver Disease)—Why the Need for a Change of Nomenclature?. The Journal of Clinical Endocrinology & Metabolism, 110(7), e2407-e2410. https://doi.org/10.1210/clinem/dgaf094
Vancouver
Gastaldelli A, Newsome PN. NAFLD vs MASLD (Metabolic Dysfunction–Associated Steatotic Liver Disease)—Why the Need for a Change of Nomenclature?. The Journal of Clinical Endocrinology & Metabolism. 2025;110(7):e2407-e2410. doi:10.1210/clinem/dgaf094
BibTeX
@article{Gastaldelli2025,
author = {Gastaldelli, Amalia and Newsome, Philip N},
title = {NAFLD vs MASLD (Metabolic Dysfunction–Associated Steatotic Liver Disease)—Why the Need for a Change of Nomenclature?},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2025},
volume = {110},
number = {7},
pages = {e2407--e2410},
doi = {10.1210/clinem/dgaf094}
}
EUVIMED